Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas

C. R. Rossi, A. Vecchiato, M. Foletto, D. Nitti, V. Ninfo, A. Fornasiero, G. Sotti, A. Tregnaghi, P. Melanotte, M. Lise

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background. Locoregional control of soft tissue sarcomas of the limbs is achieved generally using a multidisciplinary approach consisting of conservative surgery combined with radiation therapy, intraarterial chemotherapy, or hyperthermic antiblastic perfusion (HAP). Before surgery, HAP seems to be the more suitable tool in decreasing tumor mass and allowing limb-sparing surgery. The authors' aim was to ascertain the activity of HAP with doxorubicin against intermediate or high grade limb tumors. Methods. In 23 patients with limb sarcomas (2 patients International Union Against Cancer Stage IIA, 4 stage IIB, 1 stage IIIA, 11 stage IIIB, and 5 stage IVB) doxorubicin was administered via HAP 4-6 weeks before surgery. The drug (bolus, 0.7-1.4 mg/kg) was perfused for 60 minutes with a tumor temperature of at least 40.5°C (range, 40.5-42.6°). Tumor necrosis was then assessed radiologically and pathologically. Results. Systemic toxicity was hematologic grade (G) 2 in 2 patients, gastrointestinal (hepatic) in 6, G1 in 2, G2 in 3, and G3 in 1; 2 patients had alopecia; locoregional toxicity (graded according to Wieberdink) was G1 or G2 in 18, G3 in 4, and G4 in 1. Tumor necrosis was more than 50% in 17 patients (74%). Limb-sparing surgery was feasible in 20 patients (91%). At present, 14 patients are alive. Six had local recurrences, and eight had distant metastases. Conclusions. Our findings show that HAP with doxorubicin is an active and well-tolerated procedure within a multidisciplinary approach to treatment of limb sarcomas.

Original languageEnglish
Pages (from-to)2140-2146
Number of pages7
JournalCancer
Volume73
Issue number8
Publication statusPublished - 1994

Fingerprint

Sarcoma
Doxorubicin
Extremities
Perfusion
Neoplasms
Necrosis
Alopecia
Radiotherapy
Neoplasm Metastasis
Recurrence
Drug Therapy
Temperature
Liver
Pharmaceutical Preparations

Keywords

  • doxorubicin
  • hyperthermia
  • limb perfusion
  • locoregional treatment
  • soft tissue sarcomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. / Rossi, C. R.; Vecchiato, A.; Foletto, M.; Nitti, D.; Ninfo, V.; Fornasiero, A.; Sotti, G.; Tregnaghi, A.; Melanotte, P.; Lise, M.

In: Cancer, Vol. 73, No. 8, 1994, p. 2140-2146.

Research output: Contribution to journalArticle

Rossi, CR, Vecchiato, A, Foletto, M, Nitti, D, Ninfo, V, Fornasiero, A, Sotti, G, Tregnaghi, A, Melanotte, P & Lise, M 1994, 'Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas', Cancer, vol. 73, no. 8, pp. 2140-2146.
Rossi, C. R. ; Vecchiato, A. ; Foletto, M. ; Nitti, D. ; Ninfo, V. ; Fornasiero, A. ; Sotti, G. ; Tregnaghi, A. ; Melanotte, P. ; Lise, M. / Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. In: Cancer. 1994 ; Vol. 73, No. 8. pp. 2140-2146.
@article{2346a9aa19ce4abf9d754e36987a8666,
title = "Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas",
abstract = "Background. Locoregional control of soft tissue sarcomas of the limbs is achieved generally using a multidisciplinary approach consisting of conservative surgery combined with radiation therapy, intraarterial chemotherapy, or hyperthermic antiblastic perfusion (HAP). Before surgery, HAP seems to be the more suitable tool in decreasing tumor mass and allowing limb-sparing surgery. The authors' aim was to ascertain the activity of HAP with doxorubicin against intermediate or high grade limb tumors. Methods. In 23 patients with limb sarcomas (2 patients International Union Against Cancer Stage IIA, 4 stage IIB, 1 stage IIIA, 11 stage IIIB, and 5 stage IVB) doxorubicin was administered via HAP 4-6 weeks before surgery. The drug (bolus, 0.7-1.4 mg/kg) was perfused for 60 minutes with a tumor temperature of at least 40.5°C (range, 40.5-42.6°). Tumor necrosis was then assessed radiologically and pathologically. Results. Systemic toxicity was hematologic grade (G) 2 in 2 patients, gastrointestinal (hepatic) in 6, G1 in 2, G2 in 3, and G3 in 1; 2 patients had alopecia; locoregional toxicity (graded according to Wieberdink) was G1 or G2 in 18, G3 in 4, and G4 in 1. Tumor necrosis was more than 50{\%} in 17 patients (74{\%}). Limb-sparing surgery was feasible in 20 patients (91{\%}). At present, 14 patients are alive. Six had local recurrences, and eight had distant metastases. Conclusions. Our findings show that HAP with doxorubicin is an active and well-tolerated procedure within a multidisciplinary approach to treatment of limb sarcomas.",
keywords = "doxorubicin, hyperthermia, limb perfusion, locoregional treatment, soft tissue sarcomas",
author = "Rossi, {C. R.} and A. Vecchiato and M. Foletto and D. Nitti and V. Ninfo and A. Fornasiero and G. Sotti and A. Tregnaghi and P. Melanotte and M. Lise",
year = "1994",
language = "English",
volume = "73",
pages = "2140--2146",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas

AU - Rossi, C. R.

AU - Vecchiato, A.

AU - Foletto, M.

AU - Nitti, D.

AU - Ninfo, V.

AU - Fornasiero, A.

AU - Sotti, G.

AU - Tregnaghi, A.

AU - Melanotte, P.

AU - Lise, M.

PY - 1994

Y1 - 1994

N2 - Background. Locoregional control of soft tissue sarcomas of the limbs is achieved generally using a multidisciplinary approach consisting of conservative surgery combined with radiation therapy, intraarterial chemotherapy, or hyperthermic antiblastic perfusion (HAP). Before surgery, HAP seems to be the more suitable tool in decreasing tumor mass and allowing limb-sparing surgery. The authors' aim was to ascertain the activity of HAP with doxorubicin against intermediate or high grade limb tumors. Methods. In 23 patients with limb sarcomas (2 patients International Union Against Cancer Stage IIA, 4 stage IIB, 1 stage IIIA, 11 stage IIIB, and 5 stage IVB) doxorubicin was administered via HAP 4-6 weeks before surgery. The drug (bolus, 0.7-1.4 mg/kg) was perfused for 60 minutes with a tumor temperature of at least 40.5°C (range, 40.5-42.6°). Tumor necrosis was then assessed radiologically and pathologically. Results. Systemic toxicity was hematologic grade (G) 2 in 2 patients, gastrointestinal (hepatic) in 6, G1 in 2, G2 in 3, and G3 in 1; 2 patients had alopecia; locoregional toxicity (graded according to Wieberdink) was G1 or G2 in 18, G3 in 4, and G4 in 1. Tumor necrosis was more than 50% in 17 patients (74%). Limb-sparing surgery was feasible in 20 patients (91%). At present, 14 patients are alive. Six had local recurrences, and eight had distant metastases. Conclusions. Our findings show that HAP with doxorubicin is an active and well-tolerated procedure within a multidisciplinary approach to treatment of limb sarcomas.

AB - Background. Locoregional control of soft tissue sarcomas of the limbs is achieved generally using a multidisciplinary approach consisting of conservative surgery combined with radiation therapy, intraarterial chemotherapy, or hyperthermic antiblastic perfusion (HAP). Before surgery, HAP seems to be the more suitable tool in decreasing tumor mass and allowing limb-sparing surgery. The authors' aim was to ascertain the activity of HAP with doxorubicin against intermediate or high grade limb tumors. Methods. In 23 patients with limb sarcomas (2 patients International Union Against Cancer Stage IIA, 4 stage IIB, 1 stage IIIA, 11 stage IIIB, and 5 stage IVB) doxorubicin was administered via HAP 4-6 weeks before surgery. The drug (bolus, 0.7-1.4 mg/kg) was perfused for 60 minutes with a tumor temperature of at least 40.5°C (range, 40.5-42.6°). Tumor necrosis was then assessed radiologically and pathologically. Results. Systemic toxicity was hematologic grade (G) 2 in 2 patients, gastrointestinal (hepatic) in 6, G1 in 2, G2 in 3, and G3 in 1; 2 patients had alopecia; locoregional toxicity (graded according to Wieberdink) was G1 or G2 in 18, G3 in 4, and G4 in 1. Tumor necrosis was more than 50% in 17 patients (74%). Limb-sparing surgery was feasible in 20 patients (91%). At present, 14 patients are alive. Six had local recurrences, and eight had distant metastases. Conclusions. Our findings show that HAP with doxorubicin is an active and well-tolerated procedure within a multidisciplinary approach to treatment of limb sarcomas.

KW - doxorubicin

KW - hyperthermia

KW - limb perfusion

KW - locoregional treatment

KW - soft tissue sarcomas

UR - http://www.scopus.com/inward/record.url?scp=0028329179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028329179&partnerID=8YFLogxK

M3 - Article

C2 - 8156518

AN - SCOPUS:0028329179

VL - 73

SP - 2140

EP - 2146

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -